Untreated obstructive sleep apnea (OSA) is linked to significant productivity losses, estimated at $180.2 billion in the US and £4.22 billion in the UK annually. The prevalence of OSA syndrome is notably high among working-age adults, yet diagnosis and treatment rates remain low.
Background
Obstructive sleep apnea (OSA) is a common condition characterized by repeated upper airway obstruction during sleep, leading to serious health and economic consequences. The condition not only affects individual health but also has substantial implications for workplace productivity. Despite its prevalence, many individuals remain undiagnosed or untreated, highlighting the need for improved screening and management strategies.
Data Highlights
Country
Annual Productivity Loss
Prevalence of OSA Syndrome
US
$180.2 billion
22.8%
UK
£4.22 billion
19.5%
Key Findings
Estimated annual productivity loss per affected worker is $3727.40 in the US and approximately £1840 in the UK.
Nearly 30% of US adults aged 18 to 64 years meet the criteria for OSA syndrome.
7% of UK adults aged 18 to 64 years meet the criteria for OSA syndrome.
Diagnosis of OSA was based on self-reported symptoms rather than objective testing, which may lead to misclassification.
Adherence to continuous positive airway pressure (CPAP) therapy is often suboptimal among patients.
The economic burden of OSA may be underestimated as the analysis did not include additional healthcare costs or accident-related expenses.
Clinical Implications
Healthcare professionals should prioritize screening for obstructive sleep apnea in working-age adults, especially those exhibiting symptoms. Enhanced awareness and adherence to CPAP therapy are crucial for mitigating the economic and health impacts associated with untreated OSA.
Conclusion
The findings underscore the significant economic burden of untreated obstructive sleep apnea, emphasizing the need for improved diagnosis and management strategies to enhance patient outcomes and workplace productivity.
